OTC Markets OTCQX - Delayed Quote USD

Starpharma Holdings Limited (SPHRY)

Compare
0.5900
0.0000
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Currency in AUD All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
8,289
8,289
2,939
4,682
1,798
Cost of Revenue
632
632
1,120
2,776
791
Gross Profit
7,657
7,657
1,819
1,906
1,007
Operating Expense
18,404
18,404
20,055
19,618
23,362
Operating Income
-10,747
-10,747
-18,236
-17,712
-22,355
Net Non Operating Interest Income Expense
1,467
1,467
1,269
217
353
Other Income Expense
559
--
135
263
1,336
Pretax Income
-8,165
-8,165
-15,638
-16,154
-19,732
Net Income Common Stockholders
-8,165
-8,165
-15,638
-16,154
-19,732
Basic EPS
-0.20
--
-0.40
-0.40
-0.50
Diluted EPS
-0.20
--
-0.40
-0.40
-0.50
Basic Average Shares
41,143.3050
--
40,903.5260
40,690.0100
39,687.5860
Diluted Average Shares
41,143.3050
--
40,903.5260
40,690.0100
39,687.5860
Net Income from Continuing & Discontinued Operation
-8,165
-8,165
-15,638
-16,154
-19,732
Normalized Income
-8,165
-8,165
-15,638
-16,154
-19,732
Interest Income
1,467
1,467
1,269
217
353
Net Interest Income
1,467
1,467
1,269
217
353
EBIT
-10,747
-10,747
-18,236
-17,712
-22,355
EBITDA
-9,632
-9,632
-17,042
-16,634
-21,421
Reconciled Cost of Revenue
632
632
1,120
2,776
791
Reconciled Depreciation
1,115
1,115
1,194
1,078
934
Net Income from Continuing Operation Net Minority Interest
-8,165
-8,165
-15,638
-16,154
-19,732
Normalized EBITDA
-9,632
-9,632
-17,042
-16,634
-21,421
6/30/2021 - 5/4/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LGND Ligand Pharmaceuticals Incorporated
99.67
-3.34%
 
PLX Protalix BioTherapeutics, Inc.
2.4609
-5.35%
 
ONVO Organovo Holdings, Inc.
1.9600
-9.68%
 
ARVN Arvinas, Inc.
6.53
-5.36%
 
VERV Verve Therapeutics, Inc.
3.5600
-7.41%
 
CMPX Compass Therapeutics, Inc.
1.5100
-5.92%
 
EXEL Exelixis, Inc.
35.50
-3.22%
 
SRNE Sorrento Therapeutics, Inc.
0.0010
0.00%
 
TGTX TG Therapeutics, Inc.
37.67
-4.25%
 
VERU Veru Inc.
0.5613
-3.46%